56.30

3.32% 1.81

After Hours: 56.30

Apogee Therapeutics Inc (APGE)

Overview News Price History Financials Discussions Forecast

Apogee Therapeutics Inc stock is traded at $56.30, with a volume of 325.82K. It is up +3.32% in the last 24 hours and up +3.34% over the past month. Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Previous Close:

$54.49

Open:

$54.49

24h Volume:

325.82K

Relative Volume:

0.86

Market Cap:

$3.09B

Revenue:

Net Income/Loss:

$-118.49M

P/E Ratio:

EPS:

Net Cash Flow:

$-110.57M

1W Performance:

+2.53%

1M Performance:

+3.34%

6M Performance:

+3.89%

1Y Performance:

+195.07%

1-Day Range:

$52.37

$57.01

1-Week Range:

$50.48

$57.01

52-Week Range:

$14.19

$72.29

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (680)

Phone

650-394-5230

Address

221 CRESCENT ST., WALTHAM

Employee

Twitter

Next Earnings Date

Latest SEC Filings

APGE's Discussions on Twitter

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-10-24	Initiated	BofA Securities	Buy
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc Stock (APGE) Latest News

08:14 AM

Apogee Therapeutics to Participate in Upcoming November Investor Conferences - Marketscreener.com

08:14 AM

Oct 31, 2024

10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey

Oct 31, 2024

Oct 27, 2024

(APGE) Investment Analysis and Advice - Stock Traders Daily

Oct 27, 2024

Oct 25, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Oct 25, 2024

Wedbush Reiterates Outperform Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat

Oct 25, 2024

Oct 24, 2024

Apogee Therapeutics Unveils Promising Phase 1 Trial Results - TipRanks

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from - GlobeNewswire

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel - The Bakersfield Californian

Oct 24, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - StockTitan

Oct 24, 2024

Oct 20, 2024

Waypoint Capital Advisors LLC Invests $36.84 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 20, 2024

Oct 18, 2024

Apogee Therapeutics (NASDAQ:APGE) Trading Down 4.1%Here's What Happened - MarketBeat

Oct 18, 2024

Oct 16, 2024

(APGE) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 16, 2024

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewswire

Oct 16, 2024

11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC - MarketBeat

Oct 16, 2024

Oct 15, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Short Interest Down 11.7% in September - MarketBeat

Oct 15, 2024

Oct 14, 2024

Millennium Management LLC Lowers Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE) - MarketBeat

Oct 14, 2024

Oct 09, 2024

Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by The Manufacturers Life Insurance Company - MarketBeat

Oct 09, 2024

Oct 08, 2024

Analyzing Apogee Therapeutics Inc. (APGE) After Recent Trading Activity - Knox Daily

Oct 08, 2024

Ratio Examination: Apogee Therapeutics Inc. (APGE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 08, 2024

Oct 07, 2024